219 related articles for article (PubMed ID: 24015339)
41. Evaluation of Clinical Outcomes and Simultaneous Digital Tracking of Daily Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Protocol for the Observational VENTASTEP Study.
Mueller C; Stollfuss B; Roitenberg A; Harder J; Richter MJ
JMIR Res Protoc; 2019 Apr; 8(4):e12144. PubMed ID: 30985279
[TBL] [Abstract][Full Text] [Related]
42. Inhaled iloprost induces long-term beneficial hemodynamic changes in patients with pulmonary arterial hypertension receiving combination therapy.
Yasuda K; Adachi S; Nishiyama I; Yoshida M; Nakano Y; Murohara T
Pulm Circ; 2022 Apr; 12(2):e12074. PubMed ID: 35514784
[TBL] [Abstract][Full Text] [Related]
43. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry.
Farber HW; Miller DP; Meltzer LA; McGoon MD
J Heart Lung Transplant; 2013 Nov; 32(11):1114-22. PubMed ID: 24035189
[TBL] [Abstract][Full Text] [Related]
44. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].
Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W
Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653
[TBL] [Abstract][Full Text] [Related]
45. Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension.
Burger CD; Wu B; Classi P; Morland K
J Manag Care Spec Pharm; 2023 Jan; 29(1):101-108. PubMed ID: 36580122
[No Abstract] [Full Text] [Related]
46. An advanced protocol-driven transition from parenteral prostanoids to inhaled trepostinil in pulmonary arterial hypertension.
Oudiz R; Agarwal M; Rischard F; De Marco T
Pulm Circ; 2016 Dec; 6(4):532-538. PubMed ID: 28090295
[TBL] [Abstract][Full Text] [Related]
47. Prostanoid therapies in the management of pulmonary arterial hypertension.
LeVarge BL
Ther Clin Risk Manag; 2015; 11():535-47. PubMed ID: 25848300
[TBL] [Abstract][Full Text] [Related]
48. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation.
Opitz CF; Wensel R; Bettmann M; Schaffarczyk R; Linscheid M; Hetzer R; Ewert R
Eur Heart J; 2003 Feb; 24(4):356-65. PubMed ID: 12581683
[TBL] [Abstract][Full Text] [Related]
49. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.
Ghofrani HA; Rose F; Schermuly RT; Olschewski H; Wiedemann R; Kreckel A; Weissmann N; Ghofrani S; Enke B; Seeger W; Grimminger F
J Am Coll Cardiol; 2003 Jul; 42(1):158-64. PubMed ID: 12849677
[TBL] [Abstract][Full Text] [Related]
50. Inhaled iloprost for the treatment of pulmonary hypertension.
Olschewski H
Eur Respir Rev; 2009 Mar; 18(111):29-34. PubMed ID: 20956120
[TBL] [Abstract][Full Text] [Related]
51. Comparison of inhaled nitric oxide with aerosolized prostacyclin or analogues for the postoperative management of pulmonary hypertension: a systematic review and meta-analysis.
Chen SH; Chen LK; Teng TH; Chou WH
Ann Med; 2020; 52(3-4):120-130. PubMed ID: 32204626
[No Abstract] [Full Text] [Related]
52. Inhaled iloprost for severe pulmonary hypertension.
Olschewski H; Simonneau G; Galiè N; Higenbottam T; Naeije R; Rubin LJ; Nikkho S; Speich R; Hoeper MM; Behr J; Winkler J; Sitbon O; Popov W; Ghofrani HA; Manes A; Kiely DG; Ewert R; Meyer A; Corris PA; Delcroix M; Gomez-Sanchez M; Siedentop H; Seeger W;
N Engl J Med; 2002 Aug; 347(5):322-9. PubMed ID: 12151469
[TBL] [Abstract][Full Text] [Related]
53. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
54. Prostacyclin for pulmonary hypertension.
Paramothayan NS; Lasserson TJ; Wells AU; Walters EH
Cochrane Database Syst Rev; 2003; (2):CD002994. PubMed ID: 12804447
[TBL] [Abstract][Full Text] [Related]
55. A systematic review of transition studies of pulmonary arterial hypertension specific medications.
Sofer A; Ryan MJ; Tedford RJ; Wirth JA; Fares WH
Pulm Circ; 2017; 7(2):326-338. PubMed ID: 28597769
[TBL] [Abstract][Full Text] [Related]
56. Acute Effect of Inhaled Iloprost in Children with Pulmonary Arterial Hypertension Associated with Simple Congenital Heart Defects.
Li Q; Dimopoulos K; Zhang C; Zhu Y; Liu Q; Gu H
Pediatr Cardiol; 2018 Apr; 39(4):757-762. PubMed ID: 29426959
[TBL] [Abstract][Full Text] [Related]
57. Experience with inhaled iloprost and bosentan in portopulmonary hypertension.
Hoeper MM; Seyfarth HJ; Hoeffken G; Wirtz H; Spiekerkoetter E; Pletz MW; Welte T; Halank M
Eur Respir J; 2007 Dec; 30(6):1096-102. PubMed ID: 17652314
[TBL] [Abstract][Full Text] [Related]
58. Acute Iloprost Inhalation Improves Right Ventricle Function in Pulmonary Artery Hypertension: A Cardiac Magnetic Resonance Study.
Li JH; Zhang HD; Wang ZZ; Lu QQ; Li D; Lian TY; Lv ZC; Jiang X; Wu Y; Ye J; Zhao S; Yang Z
Front Pharmacol; 2018; 9():1550. PubMed ID: 30719004
[No Abstract] [Full Text] [Related]
59. Inhalation of repurposed drugs to treat pulmonary hypertension.
Gessler T
Adv Drug Deliv Rev; 2018 Aug; 133():34-44. PubMed ID: 29886070
[TBL] [Abstract][Full Text] [Related]
60. Effect of inhaled iloprost during off-medication time in patients with pulmonary arterial hypertension.
Mereles D; Ewert R; Lodziewski S; Borst MM; Benz A; Olschewski H; Grünig E
Respiration; 2007; 74(5):498-502. PubMed ID: 17449958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
